Introduction: Acute traumatic intraparenchymal hematoma (tICH) expansion is a major cause of clinical deterioration after brain contusion. Here, an accurate prediction tool for acute tICH expansion is proposed.
Methods: A multicenter hospital-based study for multivariable prediction model was conducted among patients (889 patients in a development dataset and 264 individuals in an external validation dataset) with initial and follow-up computed tomography (CT) imaging for tICH volume evaluation. Semi-automated software was employed to assess tICH expansion. Two multivariate predictive models for acute tICH expansion were developed and externally validated.
Results: A total of 198 (22.27%) individuals had remarkable acute tICH expansion. The novel Traumatic Parenchymatous Hematoma Expansion Aid (TPHEA) model retained several variables, including age, coagulopathy, baseline tICH volume, time to baseline CT time, subdural hemorrhage, a novel imaging marker of multihematoma fuzzy sign, and an inflammatory index of monocyte-to-lymphocyte ratio. Compared with multihematoma fuzzy sign, monocyte-to-lymphocyte ratio, and the basic model, the TPHEA model exhibited optimal discrimination, calibration, and clinical net benefits for patients with acute tICH expansion. A TPHEA nomogram was subsequently introduced from this model to facilitate clinical application. In an external dataset, this device showed good predicting performance for acute tICH expansion.
Conclusions: The main predictive factors in the TPHEA nomogram are the monocyte-to-lymphocyte ratio, baseline tICH volume, and multihematoma fuzzy sign. This user-friendly tool can estimate acute tICH expansion and optimize personalized treatments for individuals with brain contusion.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857351 | PMC |
| http://dx.doi.org/10.1007/s40120-021-00306-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An updated review for clinical and radiological predictors of acute intraparenchymal hematoma progression in cerebral contusion.
Heliyon
November 2024
Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Backgrounds: The rapid expansion of an intraparenchymal hematoma following cerebral contusion often results in high mortality rates and a poor prognosis. Effective tools are essential for predicting and monitoring the incidence of traumatic intraparenchymal hematoma (tICH) and identifying patients at high risk of tICH expansion. This enables timely surgical interventions and appropriate medical management.
View Article and Find Full Text PDFOutcome 1 year after ICH: Data from the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial.
Eur Stroke J
July 2024
Stroke Medicine, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham, UK.
Article Synopsis
- The TICH-2 trial found no significant improvements in death and dependency outcomes at 90 days after administering tranexamic acid for intracerebral hemorrhage (ICH), but it suggested that recovery from stroke may take longer than three months.
- The study included 2325 patients, with outcomes assessed at one year using various scales, and showed that tranexamic acid did not lead to better functional results at that time, though it associated with a lower mortality rate.
- Despite the potential for reduced mortality, the conclusion emphasizes caution as these findings come from a secondary analysis of a trial that did not show overall benefits.
The Effect of Tranexamic Acid on Neurosurgical Intervention in Spontaneous Intracerebral Hematoma: Data From 121 Surgically Treated Participants From the Tranexamic Acid in IntraCerebral Hemorrhage-2 Randomized Controlled Trial.
Neurosurgery
September 2024
Stroke Trials Unit, Mental Health & Clinical Neurosciences, Queen's Medical Centre, School of Medicine, University of Nottingham, Nottingham , UK.
Background And Objectives: An important proportion of patients with spontaneous intracerebral hemorrhage (ICH) undergo neurosurgical intervention to reduce mass effect from large hematomas and control the complications of bleeding, including hematoma expansion and hydrocephalus. The Tranexamic acid (TXA) for hyperacute primary IntraCerebral Hemorrhage (TICH-2) trial demonstrated that tranexamic acid (TXA) reduces the risk of hematoma expansion. We hypothesized that TXA would reduce the frequency of surgery (primary outcome) and improve functional outcome at 90 days in surgically treated patients in the TICH-2 data set.
View Article and Find Full Text PDFUtility of Routine Surveillance Head Computed Tomography After Receiving Therapeutic Anticoagulation in Patients with Acute Traumatic Intracranial Hemorrhage.
World Neurosurg
May 2024
Department of Neurological Surgery, University of Washington, Seattle, Washington; Harborview Injury Prevention Research Center, University of Washington, Seattle, Washington.
Introduction: Patients with traumatic intracranial hemorrhage (tICH) are at increased risk of venous thromboembolism and may require anticoagulation. We evaluated the utility of surveillance computed tomography (CT) in patients with tICH who required therapeutic anticoagulation.
Methods: This single institution, retrospective study included adult patients with tICH who required anticoagulation within 4 weeks and had a surveillance head CT within 24 hours of reaching therapeutic anticoagulation levels.
Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors - Individual patient data analysis of ANNEXA-4 and TICH-NOAC.
Int J Stroke
June 2024
Department of Neurology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland.
Article Synopsis
- The study looked at how well a drug called andexanet alfa works compared to other treatments for older people who had brain bleeding because of certain blood thinners.
- They analyzed data from two different studies with 243 patients, focusing on whether their brain bleeding got worse and if they had any serious complications after treatment.
- The results showed that patients treated with andexanet alfa had a lower chance of their bleeding getting worse compared to those who got other treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!